These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15143346)

  • 1. Omomyc expression in skin prevents Myc-induced papillomatosis.
    Soucek L; Nasi S; Evan GI
    Cell Death Differ; 2004 Sep; 11(9):1038-45. PubMed ID: 15143346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
    Soucek L; Jucker R; Panacchia L; Ricordy R; Tatò F; Nasi S
    Cancer Res; 2002 Jun; 62(12):3507-10. PubMed ID: 12067996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
    Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
    Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myc lacks E2F1's ability to suppress skin carcinogenesis.
    Rounbehler RJ; Schneider-Broussard R; Conti CJ; Johnson DG
    Oncogene; 2001 Aug; 20(38):5341-9. PubMed ID: 11536046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CCAAT/enhancer binding protein family DNA binding in mouse epidermis prevents and regresses papillomas.
    Oh WJ; Rishi V; Orosz A; Gerdes MJ; Vinson C
    Cancer Res; 2007 Feb; 67(4):1867-76. PubMed ID: 17308129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation.
    Carlson H; Ota S; Song Y; Chen Y; Hurlin PJ
    Oncogene; 2002 May; 21(24):3827-35. PubMed ID: 12032820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas.
    Cavin LG; Wang F; Factor VM; Kaur S; Venkatraman M; Thorgeirsson SS; Arsura M
    Mol Cancer Res; 2005 Jul; 3(7):403-12. PubMed ID: 16046551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation of Ha-ras and Bcl-2 during multistep skin carcinogenesis.
    Lee S; Chari NS; Kim HW; Wang X; Roop DR; Cho SH; DiGiovanni J; McDonnell TJ
    Mol Carcinog; 2007 Dec; 46(12):949-57. PubMed ID: 17538944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic analysis of myc and telomerase interactions in vivo.
    Flores I; Evan G; Blasco MA
    Mol Cell Biol; 2006 Aug; 26(16):6130-8. PubMed ID: 16880523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted expression of c-Myc in the epidermis alters normal proliferation, differentiation and UV-B induced apoptosis.
    Waikel RL; Wang XJ; Roop DR
    Oncogene; 1999 Aug; 18(34):4870-8. PubMed ID: 10490820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proto-oncogene c-myc in hematopoietic development and leukemogenesis.
    Hoffman B; Amanullah A; Shafarenko M; Liebermann DA
    Oncogene; 2002 May; 21(21):3414-21. PubMed ID: 12032779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of human papillomavirus and relevant tumor suppressors and oncoproteins in laryngeal tumors.
    Manjarrez ME; Ocadiz R; Valle L; Pacheco C; Marroquin A; De la Torre C; Selman M; Gariglio P
    Clin Cancer Res; 2006 Dec; 12(23):6946-51. PubMed ID: 17145812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model.
    Rounbehler RJ; Rogers PM; Conti CJ; Johnson DG
    Cancer Res; 2002 Jun; 62(11):3276-81. PubMed ID: 12036945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia.
    Flores I; Murphy DJ; Swigart LB; Knies U; Evan GI
    Oncogene; 2004 Aug; 23(35):5923-30. PubMed ID: 15208685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice.
    de La Coste A; Mignon A; Fabre M; Gilbert E; Porteu A; Van Dyke T; Kahn A; Perret C
    Cancer Res; 1999 Oct; 59(19):5017-22. PubMed ID: 10519417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation.
    Vaqué JP; Fernández-García B; García-Sanz P; Ferrandiz N; Bretones G; Calvo F; Crespo P; Marín MC; León J
    Mol Cancer Res; 2008 Feb; 6(2):325-39. PubMed ID: 18314492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells.
    Cheung RS; Brooling JT; Johnson MM; Riehle KJ; Campbell JS; Fausto N
    Carcinogenesis; 2007 Dec; 28(12):2624-31. PubMed ID: 17698969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.
    Jansen AP; Camalier CE; Colburn NH
    Cancer Res; 2005 Jul; 65(14):6034-41. PubMed ID: 16024603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism.
    Knies-Bamforth UE; Fox SB; Poulsom R; Evan GI; Harris AL
    Cancer Res; 2004 Sep; 64(18):6563-70. PubMed ID: 15374969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes.
    Brennan D; Hu Y; Joubeh S; Choi YW; Whitaker-Menezes D; O'Brien T; Uitto J; Rodeck U; Mahoney MG
    J Cell Sci; 2007 Mar; 120(Pt 5):758-71. PubMed ID: 17284515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.